Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics Statistics

Total Valuation

RNA has a market cap or net worth of $222.37 million. The enterprise value is -$41.26 million.

Market Cap	222.37M
Enterprise Value	-41.26M

Important Dates

The last earnings date was Thursday, May 14, 2026, after market close.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

RNA has 17.11 million shares outstanding.

Current Share Class	17.11M
Shares Outstanding	17.11M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+10.25%
Owned by Insiders (%)	2.80%
Owned by Institutions (%)	81.69%
Float	15.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.10
Forward PS	n/a
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.04, with a Debt / Equity ratio of 0.01.

Current Ratio	13.04
Quick Ratio	12.91
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-21.98%
Weighted Average Cost of Capital (WACC)	9.25%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-142,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	0.93
52-Week Price Change	n/a
50-Day Moving Average	13.32
200-Day Moving Average	n/a
Relative Strength Index (RSI)	50.39
Average Volume (20 Days)	201,638

Short Selling Information

The latest short interest is 3.43 million, so 6.62% of the outstanding shares have been sold short.

Short Interest	3.43M
Short Previous Month	3.02M
Short % of Shares Out	6.62%
Short % of Float	n/a
Short Ratio (days to cover)	7.13

Income Statement

In the last 12 months, RNA had revenue of $36.68 million and -$58.69 million in losses. Loss per share was -$3.43.

Revenue	36.68M
Gross Profit	-12.07M
Operating Income	-59.46M
Pretax Income	-58.83M
Net Income	-58.69M
EBITDA	-59.04M
EBIT	-59.46M
Loss Per Share	-$3.43

Balance Sheet

The company has $267.85 million in cash and $2.68 million in debt, with a net cash position of $265.17 million or $15.50 per share.

Cash & Cash Equivalents	267.85M
Total Debt	2.68M
Net Cash	265.17M
Net Cash Per Share	$15.50
Equity (Book Value)	234.10M
Book Value Per Share	13.69
Working Capital	263.66M

Cash Flow

In the last 12 months, operating cash flow was -$61.17 million and capital expenditures -$3.54 million, giving a free cash flow of -$64.71 million.

Operating Cash Flow	-61.17M
Capital Expenditures	-3.54M
Depreciation & Amortization	421,000
Net Borrowing	n/a
Free Cash Flow	-64.71M
FCF Per Share	-$3.78

Margins

Gross margin is -32.91%, with operating and profit margins of -162.10% and -159.99%.

Gross Margin	-32.91%
Operating Margin	-162.10%
Pretax Margin	-160.38%
Profit Margin	-159.99%
EBITDA Margin	-160.95%
EBIT Margin	-162.10%
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-26.21%
FCF Yield	-28.90%

Analyst Forecast

The average price target for RNA is $25.00, which is 92.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.00
Price Target Difference	92.31%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 2.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.84
Piotroski F-Score	1